BAYRY
A very pricey side hustle
Bayer just found a buyer for a slice of its long-acting reversible contraceptives business, and the buyer is Apollo. The asset manager agreed to pay $3.4 billion for a minority stake, which is corporate-speak for: Bayer gets a big pile of cash, and Apollo gets exposure to a business that still has room to grow.
Why this matters
This isn’t a blockbuster M&A deal where one company swallows another whole. It’s more like Bayer is trimming the hedge while keeping the house. That can be a smart move if you want to raise cash, simplify the portfolio, or squeeze value out of a business unit without selling the whole thing.
For you as an investor, the key question is whether Bayer is using this to sharpen its focus or just plugging holes. Either way, the deal gives the company liquidity and may help it keep funding the parts of the business that actually move the needle.
Big picture
Minority-stake deals can be the financial equivalent of selling half your sneakers collection while keeping your favorite pair. You still own the thing, but now there’s money in the bank and a new partner at the table. Big picture: Bayer is still in reshaping mode, and this sale suggests management is willing to get creative to unlock value.